Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

All NewsJune 3, 2025

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent